Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.51USD
2 Dec 2016
Change (% chg)

$0.34 (+6.47%)
Prev Close
$5.18
Open
$5.19
Day's High
$5.51
Day's Low
$5.19
Volume
176,817
Avg. Vol
192,337
52-wk High
$10.97
52-wk Low
$1.64

BCRX.OQ

Chart for BCRX.OQ

About

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular... (more)

Overall

Beta: 3.88
Market Cap(Mil.): $446.24
Shares Outstanding(Mil.): 73.76
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.93 -- --
ROI: -108.83 -1.09 14.95
ROE: -171.76 -2.39 16.29

BRIEF-Biocryst Q3 loss $0.16/shr

* Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

Nov 07 2016

BRIEF-Biocryst Pharmaceuticals closes $23 million senior credit facility

* Biocryst closes $23 million senior credit facility Source text for Eikon: Further company coverage:

Sep 26 2016

BRIEF-Biocryst announces results for BCX4430 delayed treatment in non-human primate model

* Announces positive study results for BCX4430 delayed treatment of ebola virus infection in a non-human primate model Source text for Eikon: Further company coverage:

Sep 07 2016

BRIEF-RTW Investments reports 5.02 pct passive stake in Biocryst

* RTW Investments reports 5.02 pct passive stake in Biocryst Pharmaceuticals as of Aug 18 - SEC filing Source text: http://bit.ly/2buwIp2 Further company coverage:

Aug 26 2016

BRIEF-D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11

* D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing Source text ( http://bit.ly/2bal6eL) Further company coverage:

Aug 22 2016

BRIEF-Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals

* Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing

Aug 17 2016

BRIEF-Felix Baker reports stake of 14.99 pct in BioCryst Pharmaceuticals

* Felix J. Baker reports a stake of 14.99% in BioCryst Pharmaceuticals Inc as of Aug 12 - SEC filing

Aug 16 2016

BRIEF-Biocryst Q2 loss per share $0.22

* Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S

Aug 04 2016

BRIEF-BioCryst receives more funding for developing treatment for hemorrhagic fever virus diseases

* Funding represents an additional $5.5 million to BioCryst for development of BCX4430 as a treatment for hemorrhagic fever viruses

Jul 05 2016

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,410 -2.00
Eisai Co., Ltd (4523.T) ¥6,514 -70.00
Roche Holding Ltd. (ROG.S) CHF220.60 -1.60
Roche Holding Ltd. (RO.S) CHF224.60 -1.10
GlaxoSmithKline plc (GSK.L) 1,467.00p -1.50
Shire PLC (SHP.L) 4,589.50p +35.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates